Brief Summary
The purpose of this study is to evaluate clinical efficacy of incorporating Epcoritamab into the salvage regimen for relapsed-refractory aggressive B-cell lymphomacancers of the lymphatic system, followed by autologous stem-cell transplantation (ASCT) and consolidation Epcoritamab.
Intervention/Treatment
- Drug: Epcoritamab.
- Autologous Stem Cell Transplanta procedure that involves replacing unhealthy blood-forming cells (stem cells) with healthy stem cells (ASCT).
- Drug: Tocilizumab.
Inclusion Criteria
- Age 18 years or older.
- Confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of DLBCL, Not-otherwise specified (NOS), Transformation of indolent B-cell lymphoma, High-grade B-cell lymphoma (HGBCL), NOS, Diffuse-large BCL (DLBCL)/HGBL with MYC and BCL2 rearrangements or Follicular large B-cell lymphoma according to WHO 2016 or 2022 criteria that has relapsed or progressed after one line of chemoimmunotherapy.
- Transplant eligible according to local assessment.
- ECOG performance status 0-2.
- Measurable disease on CT scan, defined as a nodal site greater than 1.5cm in longest axis or an extranodal site greater than 1.0cm in longest axis AND baseline fluorodeoxyglucose (FDG) positron emission tomography (PET) scans must demonstrate positive lesion compatible with CT defined anatomical tumoura tissue mass that forms from groups of unhealthy cells sites.
- Histological confirmation of tumour CD20 positivity, analysed by immunohistochemistry, on a pre-enrolment tissuea group of cells that work together to perform a function sample performed after most recent prior therapy.
- Adequate renal function:
- Creatinine clearance greater than 45mL per min (Cockcroft Gault formula).
- Adequate hepatic function:
- Aspartate transaminase (AST) and alanine transaminase (ALT) less than or equal to 3x Upper Limit of Normal (ULN).
- Bilirubin less than or equal to 1.5xULN or less than or equal to 3 if documented liver involvement and/or Gilbert’s disease.
- Adequate haematologic function:
- Haemoglobin greater than or equal to 90g/L (transfusion support permitted).
- Absolute neutrophil count greater than or equal to 1.0 x 109 per L; growth factor support allowed in case of bone marrowsoft, spongy tissue found in bones that makes blood cells involvement.
- Platelet count greater than 75 x 109 per L or greater than or equal to 50 x 109 per L if documented marrow involvement.
- Able to take oral medications.
- Adequate washout of prior therapies:
- At least 4 weeks since last dosethe amount of medication taken of immunochemotherapy, radio-conjugated or toxin-conjugated compound, or other investigational anti-cancer therapy.
- At least 6 weeks since chimeric antigen-receptor T-cell therapy.
- Resolution of toxicities from prior therapy to a gradea description of how abnormal cancer cells and tissue look under a microscope when compared to healthy cells that does not contraindicate trial participation in the opinion of the investigator.
- If receiving glucocorticoid treatment at screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening, treatment must be tapered down and administered with a maximum of 25 mg daily in the last 14 days before the first dose of Epcoritamab.
- Before the first dose of Epcoritamab, during the trial and for 12 months after last administration of Epcoritamab, a woman must be either:
- Not of childbearing potential, defined as: premenarchal; postmenopausal (greater than 45 years of age with amenorrhea for at least 12 months or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormonea chemical substance produced by glands in the endocrine system that regulates various functions in the body [FSH] level greater than 40 IU per L or mIU per mL); permanently sterilized (e.g., bilateralaffecting both sides tubal occlusion [which includes tubal ligation procedures as consistent with local regulations], hysterectomycomplete or partial removal of the uterus, bilateral salpingectomyremoval of one (unilateral) or both (bilateral) fallopian tubes, bilateral oophorectomyremoval of one (unilateral) or both (bilateral) ovaries); or otherwise be incapable of pregnancy.
- Of childbearing potential and practicing a highly effective method of birth control (as defined by the EU Clinical Trial Facilitation Group) consistent with local regulations regarding the use of birth control methods for patients participating in clinical trialsresearch studies performed to test new treatments, tests or procedures and evaluate their effectiveness on various diseases: e.g., established use of oral, injected or implanted combined (estradiol and progesterone containing) hormonal contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS); male partner sterilization (the vasectomized partner should be the sole partner for that patient); true abstinence (when this is in line with the preferred and usual lifestyle of the patient)
* If the childbearing potential changes after start of the trial (e.g., woman who is not heterosexually active becomes active, premenarchal woman experiences menarche) a woman must begin a highly effective method of birth control.
- A man who is sexually active with a woman of childbearing potential must agree to use a barrier method of birth control (that is the use of condom) during the trial and for 12 months after receiving the last dose of Epcoritamab.
- Women must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the trial and for 12 months after receiving the last dose of Epcoritamab. Men must also not donate sperm during the trial and for 12 months after receiving the last dose of Epcoritamab.
- The patient understands the purpose of the trial and procedures required for the trial and is capable of giving signed informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment. which includes compliance with the requirements (no medical or psychiatric reason precluding participation) and restrictions listed in the informed consent form (ICF) and in this protocol.